Eligibility for vericiguat in a real-world, contemporary heart failure population.

ABSTRACT:

Aims

Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real-world data on how many patients could be eligible for vericiguat therapy derive from outdated registries, we aimed to assess eligibility in a prospective cohort of patients with HF.

Methods and results

Data from consecutive HF patients undergoing an elective ambulatory visit at five university hospitals from 3 July to 28 July 2023 were collected. Independent investigators assessed which patients (i) met the eligibility criteria of the VICTORIA trial, (ii) complied with HF guideline recommendations, (iii) met regulatory agency criteria, or (iv) met criteria for refundability

SUBMITTER: Vergaro G 

PROVIDER: S-EPMC11631227 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature